title: ASCO Reveals Additional Promising Results With Immunotherapies.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology; D000068818:Cetuximab / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D053843:DNA Mismatch Repair / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors; D000074324:Ipilimumab; D008495:Medical Oncology; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D000077594:Nivolumab; D012955:Societies, Medical; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; C576710:IDO1 protein, human; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D000074324:Ipilimumab; D000077594:Nivolumab; C582435:pembrolizumab; D000068818:Cetuximab